Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 34 | 2021 | 2303 | 2.020 |
Why?
|
| Cognition Disorders | 4 | 2013 | 233 | 1.190 |
Why?
|
| Anti-HIV Agents | 10 | 2018 | 420 | 1.100 |
Why?
|
| Monocytes | 11 | 2018 | 257 | 1.010 |
Why?
|
| Cerebrovascular Disorders | 2 | 2012 | 37 | 0.800 |
Why?
|
| HIV-1 | 8 | 2018 | 706 | 0.650 |
Why?
|
| Middle Aged | 37 | 2021 | 10129 | 0.590 |
Why?
|
| Cognition | 5 | 2018 | 398 | 0.580 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2018 | 221 | 0.540 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 16 | 0.540 |
Why?
|
| Anti-Retroviral Agents | 7 | 2018 | 147 | 0.530 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 40 | 0.530 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 56 | 0.520 |
Why?
|
| Cerebral Cortex | 2 | 2013 | 290 | 0.490 |
Why?
|
| Male | 42 | 2021 | 20025 | 0.480 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 11 | 0.470 |
Why?
|
| Mucuna | 1 | 2013 | 1 | 0.460 |
Why?
|
| Dizziness | 1 | 2013 | 7 | 0.450 |
Why?
|
| Levodopa | 1 | 2013 | 20 | 0.450 |
Why?
|
| Headache Disorders, Primary | 1 | 2013 | 1 | 0.440 |
Why?
|
| Abdominal Pain | 1 | 2013 | 24 | 0.440 |
Why?
|
| Post-Traumatic Headache | 1 | 2013 | 3 | 0.440 |
Why?
|
| Female | 41 | 2021 | 20969 | 0.440 |
Why?
|
| Dementia | 2 | 2014 | 131 | 0.440 |
Why?
|
| Hippocampus | 2 | 2016 | 561 | 0.430 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 20 | 0.420 |
Why?
|
| Brain Injuries | 1 | 2013 | 121 | 0.380 |
Why?
|
| Viral Load | 4 | 2021 | 312 | 0.380 |
Why?
|
| Adult | 24 | 2021 | 11712 | 0.370 |
Why?
|
| Humans | 44 | 2021 | 37093 | 0.370 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 13 | 0.370 |
Why?
|
| Aging | 6 | 2016 | 664 | 0.340 |
Why?
|
| Cross-Sectional Studies | 16 | 2021 | 2721 | 0.330 |
Why?
|
| Multilingualism | 1 | 2009 | 46 | 0.330 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 485 | 0.300 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 664 | 0.300 |
Why?
|
| Central Nervous System | 2 | 2018 | 135 | 0.280 |
Why?
|
| RNA, Viral | 3 | 2018 | 301 | 0.280 |
Why?
|
| Depression | 1 | 2013 | 712 | 0.270 |
Why?
|
| Inflammation | 5 | 2018 | 618 | 0.270 |
Why?
|
| Macrophages | 3 | 2014 | 439 | 0.260 |
Why?
|
| Lipoproteins | 3 | 2014 | 64 | 0.260 |
Why?
|
| Viremia | 2 | 2018 | 42 | 0.260 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2021 | 189 | 0.240 |
Why?
|
| Neuropsychological Tests | 5 | 2018 | 259 | 0.240 |
Why?
|
| Hawaii | 9 | 2018 | 1929 | 0.230 |
Why?
|
| Aged | 9 | 2021 | 6741 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 481 | 0.230 |
Why?
|
| Brain | 3 | 2021 | 1346 | 0.210 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2013 | 12 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 2379 | 0.210 |
Why?
|
| Interleukin-6 | 2 | 2013 | 153 | 0.210 |
Why?
|
| Risk Factors | 8 | 2015 | 3562 | 0.200 |
Why?
|
| Prospective Studies | 3 | 2015 | 1378 | 0.200 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 61 | 0.190 |
Why?
|
| DNA, Viral | 2 | 2013 | 304 | 0.190 |
Why?
|
| Prevalence | 2 | 2017 | 1455 | 0.180 |
Why?
|
| Atrophy | 3 | 2016 | 42 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 234 | 0.180 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 13 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 21 | 0.170 |
Why?
|
| Benzoxazines | 1 | 2018 | 46 | 0.160 |
Why?
|
| Galectins | 1 | 2018 | 28 | 0.160 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 26 | 0.160 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 29 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2018 | 121 | 0.160 |
Why?
|
| Leukoaraiosis | 2 | 2008 | 2 | 0.160 |
Why?
|
| AIDS Dementia Complex | 3 | 2014 | 102 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 144 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2018 | 111 | 0.160 |
Why?
|
| Headache | 1 | 2017 | 19 | 0.150 |
Why?
|
| Neurocysticercosis | 1 | 2017 | 30 | 0.150 |
Why?
|
| Epilepsy | 1 | 2017 | 43 | 0.140 |
Why?
|
| Blood Glucose | 3 | 2014 | 353 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 22 | 0.140 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 35 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 357 | 0.130 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 3 | 0.130 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 20 | 0.130 |
Why?
|
| Brachial Artery | 1 | 2015 | 28 | 0.130 |
Why?
|
| Brain Ischemia | 2 | 2008 | 184 | 0.130 |
Why?
|
| Amblyopia | 1 | 2015 | 13 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2016 | 85 | 0.130 |
Why?
|
| Vasodilation | 1 | 2015 | 65 | 0.130 |
Why?
|
| Vision Screening | 1 | 2015 | 21 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 28 | 0.130 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 32 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 85 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 400 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 175 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1130 | 0.120 |
Why?
|
| Cyclohexanes | 1 | 2014 | 30 | 0.120 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 46 | 0.120 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 62 | 0.120 |
Why?
|
| Comorbidity | 2 | 2016 | 623 | 0.120 |
Why?
|
| Triazoles | 1 | 2014 | 86 | 0.120 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2014 | 31 | 0.120 |
Why?
|
| Carotid Arteries | 1 | 2013 | 28 | 0.120 |
Why?
|
| Polyneuropathies | 1 | 2013 | 10 | 0.120 |
Why?
|
| Reflex | 1 | 2013 | 34 | 0.110 |
Why?
|
| Cholesterol | 1 | 2014 | 205 | 0.110 |
Why?
|
| Social Work | 1 | 2013 | 49 | 0.110 |
Why?
|
| Dopamine Agents | 1 | 2013 | 25 | 0.110 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 70 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2015 | 484 | 0.110 |
Why?
|
| Tension-Type Headache | 1 | 2013 | 1 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2016 | 325 | 0.110 |
Why?
|
| Niacin | 1 | 2013 | 22 | 0.110 |
Why?
|
| Migraine Disorders | 1 | 2013 | 7 | 0.110 |
Why?
|
| Albuminuria | 1 | 2013 | 76 | 0.110 |
Why?
|
| Cerebellum | 1 | 2013 | 73 | 0.110 |
Why?
|
| Calcium | 1 | 2016 | 480 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 610 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2013 | 208 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2014 | 177 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 13 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 215 | 0.110 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 33 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 18 | 0.100 |
Why?
|
| Oxidative Stress | 2 | 2016 | 938 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2014 | 184 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 105 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2017 | 2026 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 253 | 0.100 |
Why?
|
| Eating | 1 | 2013 | 166 | 0.100 |
Why?
|
| Hospitalization | 1 | 2014 | 388 | 0.100 |
Why?
|
| Psychological Tests | 1 | 2011 | 53 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 136 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2014 | 1492 | 0.100 |
Why?
|
| Mitochondria | 1 | 2014 | 487 | 0.100 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.090 |
Why?
|
| Memory | 1 | 2012 | 170 | 0.090 |
Why?
|
| Educational Status | 1 | 2012 | 313 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 308 | 0.090 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 190 | 0.090 |
Why?
|
| Cell Movement | 1 | 2013 | 571 | 0.090 |
Why?
|
| Logistic Models | 1 | 2013 | 923 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 51 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 898 | 0.090 |
Why?
|
| Papilledema | 1 | 2009 | 1 | 0.080 |
Why?
|
| Pseudotumor Cerebri | 1 | 2009 | 2 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 854 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 289 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 145 | 0.080 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2009 | 58 | 0.080 |
Why?
|
| Phenotype | 3 | 2016 | 689 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 661 | 0.080 |
Why?
|
| Time Factors | 1 | 2013 | 1742 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 24 | 0.070 |
Why?
|
| Incidence | 1 | 2010 | 922 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 885 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2018 | 77 | 0.070 |
Why?
|
| Age Factors | 3 | 2018 | 1033 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2016 | 57 | 0.060 |
Why?
|
| Zidovudine | 2 | 2015 | 34 | 0.060 |
Why?
|
| Receptors, IgG | 2 | 2014 | 50 | 0.060 |
Why?
|
| Atherosclerosis | 2 | 2014 | 134 | 0.060 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neopterin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2018 | 40 | 0.040 |
Why?
|
| Alkynes | 1 | 2018 | 50 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2014 | 753 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 56 | 0.040 |
Why?
|
| Taenia solium | 1 | 2017 | 5 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2013 | 646 | 0.040 |
Why?
|
| HIV | 1 | 2016 | 98 | 0.030 |
Why?
|
| Los Angeles | 1 | 2017 | 380 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 550 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 59 | 0.030 |
Why?
|
| Stavudine | 1 | 2015 | 13 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 48 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 19 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 159 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 236 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 214 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 46 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 61 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 215 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 305 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 174 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 28 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 207 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 88 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 739 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 60 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 352 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 601 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 461 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 60 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 267 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 112 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 108 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 1046 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 928 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 356 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 61 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 674 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1418 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1015 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4268 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 253 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 602 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1369 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2008 | 48 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 97 | 0.020 |
Why?
|
| Survivors | 1 | 2008 | 136 | 0.020 |
Why?
|
| Linear Models | 1 | 2007 | 275 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 238 | 0.020 |
Why?
|
| Smoking | 1 | 2008 | 940 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 796 | 0.010 |
Why?
|
| Child | 1 | 2009 | 3131 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 15081 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 5363 | 0.010 |
Why?
|